Israel Kanaan Blaas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Israel Kanaan Blaas has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- João Mauricio Castaldelli-Maia
Departamento de Psiquiatria, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, Sao Paulo, Brazil
7 shared publications - Julio Torales
Universidad Nacional de Asunción, San Lorenzo, Paraguay
5 shared publications - Antonio Ventriglio
Department of Clinical and Experimental Medicine, University of Foggia, Italy
4 shared publications Antonio Ventriglio
Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy
3 shared publicationsGislaine Koch Gimenes
Perdizes Institute (IPer), Clinics Hospital (HCFMUSP), Medical School, University of São Paulo, São Paulo, Brazil
3 shared publications- Guilherme Trevizan Kortas
Department and Institute of Psychiatry, University of Sao Paulo, Sao Paulo, Brazil
3 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by SAGE Publications in International Journal of Social Psychiatry
- Vol. 72 (7) , 2112-2132
The World Psychiatric Association (WPA) Guideline on Schizophrenia Spectrum Disorders Management for Low- and Middle-Income Countries
There is a pressing need to address the unique challenges of managing Schizophrenia Spectrum Disorders (SSD) in Low- and Middle-Income Countries (LMICs), where mental health resources are scarce and unevenly distributed. To develop this evidence-based guideline, we conducted a systematic review of the literature, followed by three rounds of Delphi surveys with experts from LMICs. The first two Delphi rounds identified and refined priority topics, while the third assessed their practical applicability in resource-limited contexts. The guideline emphasizes early intervention, continuity of care, and the integration of psychosocial interventions with pharmacological treatment, while explicitly tailoring recommendations to the realities of LMICs. Antipsychotic medications remain central, with second-generation agents recommended as first-line treatment for acute psychosis where available, but with recognition that first-generation agents are often the only accessible option. The guideline also discourages mega-dosing and unnecessary polypharmacy—common practices in some LMICs—in favor of rational monotherapy at the lowest effective dose. Psychosocial interventions are positioned as critical but are reframed for scalability: psychoeducation for patients and families, task-sharing to community health workers and trained lay providers, and reliance on peer support and faith-based networks where specialist services are lacking. The guideline stresses comprehensive care addressing physical, mental, and social needs, including vocational rehabilitation and housing support, while acknowledging barriers such as stigma, insecurity, and climate-related disruptions. Cultural adaptation is emphasized throughout, aligning interventions with local beliefs, social norms, and community structures to promote engagement, adherence, and sustainable outcomes.
- 7 August 2026
- Published by SAGE Publications in International Journal of Social Psychiatry
- Vol. 72 (7) , 2112-2132
Open AccessThe World Psychiatric Association (WPA) Guideline on Schizophrenia Spectrum Disorders Management for Low- and Middle-Income Countries
There is a pressing need to address the unique challenges of managing Schizophrenia Spectrum Disorders (SSD) in Low- and Middle-Income Countries (LMICs), where mental health resources are scarce and unevenly distributed. To develop this evidence-based guideline, we conducted a systematic review of the literature, followed by three rounds of Delphi surveys with experts from LMICs. The first two Delphi rounds identified and refined priority topics, while the third assessed their practical applicability in resource-limited contexts. The guideline emphasizes early intervention, continuity of care, and the integration of psychosocial interventions with pharmacological treatment, while explicitly tailoring recommendations to the realities of LMICs. Antipsychotic medications remain central, with second-generation agents recommended as first-line treatment for acute psychosis where available, but with recognition that first-generation agents are often the only accessible option. The guideline also discourages mega-dosing and unnecessary polypharmacy—common practices in some LMICs—in favor of rational monotherapy at the lowest effective dose. Psychosocial interventions are positioned as critical but are reframed for scalability: psychoeducation for patients and families, task-sharing to community health workers and trained lay providers, and reliance on peer support and faith-based networks where specialist services are lacking. The guideline stresses comprehensive care addressing physical, mental, and social needs, including vocational rehabilitation and housing support, while acknowledging barriers such as stigma, insecurity, and climate-related disruptions. Cultural adaptation is emphasized throughout, aligning interventions with local beliefs, social norms, and community structures to promote engagement, adherence, and sustainable outcomes.
- Open Access
- 1 February 2026
- Published by Catedra de Socioantropologia, Universidad Nacional de Asuncion in Medicina Clínica y Social
- Vol. 10 (1) , e805
Prevalence and Predictors of Anxiety Severity Among Health Sciences Students: A Cross-Sectional Study Using the GAD-7 Scale
Introduction: Anxiety symptoms were highly prevalent among university students, particularly those enrolled in healthcare programs, and were associated with significant academic and functional impairment. Objective: This study aimed to evaluate the prevalence and severity of anxiety symptoms using the GAD-7 scale and to identify associated factors among healthcare undergraduate students. Methodology: A cross-sectional study was conducted with 336 undergraduate students from eight healthcare programs at a Brazilian university. Data were collected through an online questionnaire including sociodemographic variables and the Generalized Anxiety Disorder-7 (GAD-7) scale. Ordinal logistic regression was performed to assess associations between anxiety severity (minimal, mild, moderate, and severe) and predictors such as age, sex, course type (Medicine vs. non-medical), and academic year. Results: The mean age was 22.0 years (SD = 4.6), and 70% of participants were female. Most students (75.3%) were enrolled in Medicine. The mean GAD-7 score was 8.0 (SD = 5.4). Anxiety severity was classified as minimal (27.4%), mild (38.1%), moderate (20.2%), and severe (14.3%), with 34.5% presenting moderate to severe anxiety. Female sex (OR = 2.3; p < 0.001) and enrollment in non-medical courses (OR = 3.2; p < 0.001) were significantly associated with greater anxiety severity. Increasing age was inversely associated with anxiety (p = 0.037). Conclusion: Anxiety symptoms were highly prevalent among healthcare students. Female sex and enrollment in non-medical programs were independent predictors of higher anxiety severity, while older age was associated with lower levels.
- 1 February 2026
- Published by Catedra de Socioantropologia, Universidad Nacional de Asuncion in Medicina Clínica y Social
- Vol. 10 (1) , e805
Open AccessPrevalence and Predictors of Anxiety Severity Among Health Sciences Students: A Cross-Sectional Study Using the GAD-7 Scale
Introduction: Anxiety symptoms were highly prevalent among university students, particularly those enrolled in healthcare programs, and were associated with significant academic and functional impairment. Objective: This study aimed to evaluate the prevalence and severity of anxiety symptoms using the GAD-7 scale and to identify associated factors among healthcare undergraduate students. Methodology: A cross-sectional study was conducted with 336 undergraduate students from eight healthcare programs at a Brazilian university. Data were collected through an online questionnaire including sociodemographic variables and the Generalized Anxiety Disorder-7 (GAD-7) scale. Ordinal logistic regression was performed to assess associations between anxiety severity (minimal, mild, moderate, and severe) and predictors such as age, sex, course type (Medicine vs. non-medical), and academic year. Results: The mean age was 22.0 years (SD = 4.6), and 70% of participants were female. Most students (75.3%) were enrolled in Medicine. The mean GAD-7 score was 8.0 (SD = 5.4). Anxiety severity was classified as minimal (27.4%), mild (38.1%), moderate (20.2%), and severe (14.3%), with 34.5% presenting moderate to severe anxiety. Female sex (OR = 2.3; p < 0.001) and enrollment in non-medical courses (OR = 3.2; p < 0.001) were significantly associated with greater anxiety severity. Increasing age was inversely associated with anxiety (p = 0.037). Conclusion: Anxiety symptoms were highly prevalent among healthcare students. Female sex and enrollment in non-medical programs were independent predictors of higher anxiety severity, while older age was associated with lower levels.
- Open Access
- 21 January 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (2) , 97
Exploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users
Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as “dual vaping”. This term describes individuals, referred to as “dual users”, who use e-cigarettes for both substances. This study aims to review and analyze existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A narrative review of the literature was conducted using PubMed. Studies focusing on individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were examined. Relevant articles were identified and thematically synthesized to provide a comprehensive overview of the topic. Results: Dual vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among dual vapers when using both nicotine and cannabis. Conclusions: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behavior.
- 21 January 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (2) , 97
Open AccessExploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users
Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as “dual vaping”. This term describes individuals, referred to as “dual users”, who use e-cigarettes for both substances. This study aims to review and analyze existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A narrative review of the literature was conducted using PubMed. Studies focusing on individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were examined. Relevant articles were identified and thematically synthesized to provide a comprehensive overview of the topic. Results: Dual vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among dual vapers when using both nicotine and cannabis. Conclusions: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behavior.
- Open Access
- 27 November 2024
- Published by MDPI AG in Preprints.org
Exploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users
Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as "dual vaping." This term describes individuals, referred to as "dual users," who use e-cigarettes for both substances. This study aims to review and analyse existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A systematic search on PubMed was performed up to August 2023. Studies investigating individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were included. Articles that met the inclusion criteria were thoroughly reviewed and analysed. Results: A total of 1,778 studies were screened, of which 53 articles were reviewed, and 25 met the inclusion criteria. Four main characteristics emerged: the demographic variables of users, their health risks, behaviours, and predisposing factors to smoking. Dual Vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual Vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among Dual Vapers when using both nicotine and cannabis. Conclusion: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behaviour.
- 27 November 2024
- Published by MDPI AG in Preprints.org
Open AccessExploring the Practice of Dual Vaping: Health Risks and Behavioral Patterns in Nicotine and Cannabis E-Cigarette Users
Background: E-cigarettes, initially designed for nicotine consumption, are now increasingly being used to smoke cannabis, resulting in a growing trend known as "dual vaping." This term describes individuals, referred to as "dual users," who use e-cigarettes for both substances. This study aims to review and analyse existing research on dual vaping, with a focus on the associated health risks and behavioral patterns. Methods: A systematic search on PubMed was performed up to August 2023. Studies investigating individuals who use electronic cigarettes for vaping tobacco and cannabis, either chronically or episodically, were included. Articles that met the inclusion criteria were thoroughly reviewed and analysed. Results: A total of 1,778 studies were screened, of which 53 articles were reviewed, and 25 met the inclusion criteria. Four main characteristics emerged: the demographic variables of users, their health risks, behaviours, and predisposing factors to smoking. Dual Vaping was found to be prevalent among younger men, White and Hispanic populations, and individuals with higher economic status and educational level. The use of one substance was shown to predispose individuals to the use of the other, often leading to concurrent use of both substances. Peer influence and positive expectations regarding e-cigarettes were identified as significant predictors of dual use. Dual Vapers exhibited a higher susceptibility to respiratory and systemic symptoms compared to those who exclusively vaped nicotine or cannabis. Moreover, a notable prevalence of psychiatric disorders, such as substance use disorders, anxiety, and depression, was observed in this group. Fruit-flavored e-cigarettes were the most preferred option among Dual Vapers when using both nicotine and cannabis. Conclusion: Current evidence is insufficient to fully elucidate the long-term impacts of dual vaping on physical and mental health, particularly when compared to individuals who have never vaped. Further studies are needed to gain a more comprehensive understanding of this behaviour.
- 5 September 2023
- Published by Taylor & Francis in International Review of Psychiatry
Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders
The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavioural support. Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated. Smoking cessation medications have been shown to be effective in reducing nicotine cravings and withdrawal symptoms and promoting smoking cessation among patients living with mental disorders. However, these medications may have implications for patients’ mental health and need to be monitored closely. The efficacy and side effects of these medications may vary depending on the patient’s psychiatric condition, medication regimen, substance use, or medical comorbidities. The purpose of this review is to synthesise the pharmacokinetics, pharmacodynamics, therapeutic effects, adverse effects, and pharmacological interactions of first- and second-line smoking cessation drugs, with an emphasis on patients suffering from mental illnesses. Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients’ needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.
- 5 September 2023
- Published by Taylor & Francis in International Review of Psychiatry
Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders
The adverse effects of smoking cessation in individuals with mental health disorders have been a point of concern, and progress in the development of treatment has been slow. The primary first-line treatments for smoking cessation are Nicotine Replacement Therapy, Bupropion, Varenicline, and behavioural support. Nortriptyline and Clonidine are second-line treatments used when the first-line treatments are not effective or are contraindicated. Smoking cessation medications have been shown to be effective in reducing nicotine cravings and withdrawal symptoms and promoting smoking cessation among patients living with mental disorders. However, these medications may have implications for patients’ mental health and need to be monitored closely. The efficacy and side effects of these medications may vary depending on the patient’s psychiatric condition, medication regimen, substance use, or medical comorbidities. The purpose of this review is to synthesise the pharmacokinetics, pharmacodynamics, therapeutic effects, adverse effects, and pharmacological interactions of first- and second-line smoking cessation drugs, with an emphasis on patients suffering from mental illnesses. Careful consideration of the risks and benefits of using smoking cessation medications is necessary, and treatment plans must be tailored to individual patients’ needs. Monitoring symptoms and medication regimens is essential to ensure optimal treatment outcomes.
- Open Access
- 15 August 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1206
Pharmacological Treatment of Alcohol Cravings
(1) Background: The treatment of substance addiction is challenging and has persisted for decades, with only a few therapeutic options. Although there are some recommendations for specific treatments for Alcohol Use Disorder (AUD), there is no specific medication used to treat alcohol cravings, which could benefit millions of patients that are suffering from alcoholism. Cravings, or the urge to use drugs, refer to the desire to experience the effects of a previously experienced psychoactive substance. (2) Methods: We included original studies of alcohol abuse or dependence extracted from a controlled, blind, pharmacological treatment study which presented measures and outcomes related to alcohol cravings. (3) Results: Specific drugs used for the treatment of alcoholism, such as Naltrexone and Acamprosate, have had the best results in relieving craving symptoms, as well as promoting abstinence. Baclofen and anticonvulsants such as Gabapentin and Topiramate have shown good results in promoting abstinence and the cessation of cravings. (4) Conclusions: Specific drugs used for the treatment of alcoholism to obtain the best results can be considered the gold standard for promoting abstinence and relieving cravings. Anticonvulsants and Baclofen also had good results, with these medications being considered as second-line ones. Varenicline is an option for alcohol dependents who also concomitantly ingest tobacco.
- 15 August 2023
- Published by MDPI AG in Brain Sciences
- Vol. 13 (8) , 1206
Open AccessPharmacological Treatment of Alcohol Cravings
(1) Background: The treatment of substance addiction is challenging and has persisted for decades, with only a few therapeutic options. Although there are some recommendations for specific treatments for Alcohol Use Disorder (AUD), there is no specific medication used to treat alcohol cravings, which could benefit millions of patients that are suffering from alcoholism. Cravings, or the urge to use drugs, refer to the desire to experience the effects of a previously experienced psychoactive substance. (2) Methods: We included original studies of alcohol abuse or dependence extracted from a controlled, blind, pharmacological treatment study which presented measures and outcomes related to alcohol cravings. (3) Results: Specific drugs used for the treatment of alcoholism, such as Naltrexone and Acamprosate, have had the best results in relieving craving symptoms, as well as promoting abstinence. Baclofen and anticonvulsants such as Gabapentin and Topiramate have shown good results in promoting abstinence and the cessation of cravings. (4) Conclusions: Specific drugs used for the treatment of alcoholism to obtain the best results can be considered the gold standard for promoting abstinence and relieving cravings. Anticonvulsants and Baclofen also had good results, with these medications being considered as second-line ones. Varenicline is an option for alcohol dependents who also concomitantly ingest tobacco.
- 27 July 2023
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 35 (5-6) , 418-433
Exploring correlates of involuntary treatment in substance use disorders: a global systematic review and meta-analysis
Given the legislative heterogeneity about involuntary treatment and psychoactive substance users, we opted to perform a systematic review and meta-analysis of the correlates of involuntary substance use disorders (SUD) treatment across different countries. We conducted research on the Pubmed database, searching for involuntary SUD treatment data worldwide. The systematic review analysed a total of 36 articles and included a sample of 47,739 patients. Our review highlights the elevated risk of involuntary treatment among male, unmarried individuals with alcohol and/or opioid use disorders. Targeted preventive and therapeutic interventions should focus on addressing the underlying factors contributing to involuntary treatment, such as psychosis, aggressiveness, suicidal ideation, legal problems, and severe social exposure. By targeting these factors and providing comprehensive care, we can strive to improve outcomes and reduce the burden of substance use disorders in this vulnerable population. It is essential to critically examine and understand the factors contributing to the selection of patients for compulsory treatment. By doing so, we can identify potential gaps or inconsistencies in the current processes and work towards ensuring that decisions regarding compulsory treatment are based on sound clinical and ethical principles.
- 27 July 2023
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 35 (5-6) , 418-433
Exploring correlates of involuntary treatment in substance use disorders: a global systematic review and meta-analysis
Given the legislative heterogeneity about involuntary treatment and psychoactive substance users, we opted to perform a systematic review and meta-analysis of the correlates of involuntary substance use disorders (SUD) treatment across different countries. We conducted research on the Pubmed database, searching for involuntary SUD treatment data worldwide. The systematic review analysed a total of 36 articles and included a sample of 47,739 patients. Our review highlights the elevated risk of involuntary treatment among male, unmarried individuals with alcohol and/or opioid use disorders. Targeted preventive and therapeutic interventions should focus on addressing the underlying factors contributing to involuntary treatment, such as psychosis, aggressiveness, suicidal ideation, legal problems, and severe social exposure. By targeting these factors and providing comprehensive care, we can strive to improve outcomes and reduce the burden of substance use disorders in this vulnerable population. It is essential to critically examine and understand the factors contributing to the selection of patients for compulsory treatment. By doing so, we can identify potential gaps or inconsistencies in the current processes and work towards ensuring that decisions regarding compulsory treatment are based on sound clinical and ethical principles.
- 21 July 2023
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 35 (5-6) , 434-449
Unravelling the landscape of Cannabis craving pharmacological treatments: a PRISMA-guided review of evidence
Currently, few treatments are available for craving in general, and none of them have received approval for cannabis craving. The objective of this review is to evaluate existing studies analysing treatments for cannabis craving and explore novel treatment possibilities for these patients. The study followed PRISMA guidelines and conducted an extensive database search. Inclusion criteria included human randomised controlled trials examining drug effects on craving symptoms. Exclusion criteria involved studies unrelated to craving, non-pharmacological treatments, duplicates, and non-English/Spanish/Portuguese articles. Our included 22 studies that investigated a wide range of compounds used for cravings related to other drugs, as well as interventions based on healthcare professionals' empirical knowledge. The current pharmacological treatments largely involve off-label drug use and the utilisation of cannabinoid-based medications, such as combinations of THC and lofexidine, oxytocin, progesterone, and N-acetylcysteine. These emerging treatments show promise and have the potential to revolutionise current clinical practices, but further investigation is needed to establish their efficacy. In this context, it is essential to consider non-pharmacological interventions, such as psychotherapy and behavioural treatments. These approaches play a crucial role in complementing pharmacological interventions and addressing the complex nature of the disorder.
- 21 July 2023
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 35 (5-6) , 434-449
Unravelling the landscape of Cannabis craving pharmacological treatments: a PRISMA-guided review of evidence
Currently, few treatments are available for craving in general, and none of them have received approval for cannabis craving. The objective of this review is to evaluate existing studies analysing treatments for cannabis craving and explore novel treatment possibilities for these patients. The study followed PRISMA guidelines and conducted an extensive database search. Inclusion criteria included human randomised controlled trials examining drug effects on craving symptoms. Exclusion criteria involved studies unrelated to craving, non-pharmacological treatments, duplicates, and non-English/Spanish/Portuguese articles. Our included 22 studies that investigated a wide range of compounds used for cravings related to other drugs, as well as interventions based on healthcare professionals' empirical knowledge. The current pharmacological treatments largely involve off-label drug use and the utilisation of cannabinoid-based medications, such as combinations of THC and lofexidine, oxytocin, progesterone, and N-acetylcysteine. These emerging treatments show promise and have the potential to revolutionise current clinical practices, but further investigation is needed to establish their efficacy. In this context, it is essential to consider non-pharmacological interventions, such as psychotherapy and behavioural treatments. These approaches play a crucial role in complementing pharmacological interventions and addressing the complex nature of the disorder.
- 19 May 2022
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 34 (3-4) , 423-431
The impact of discrimination on substance use disorders among sexual minorities
This paper aimed to review the literature regarding the impact of discrimination on substance use disorders among Sexual Minorities (SM), with a focus on alcohol, opioids, stimulants, polydrug use, chemsex, cannabis and tobacco, as well as inequalities in the access to health care services. It is alarmingly clear that SM report higher rates of morbidity if compared to the general population. Health care delivery inequalities have also been reported in this special population. Also, the lack of data from low- and middle-income countries on substance use among SM is a major concern. Certainly, discrimination play a key-role among leading factors to substance abuse, continued use, disorders, and lower levels of preventive and treatment interventions. However, it may be difficult to estimate the impact of discrimination because of the lack of research data and different methodologies of literature studies. Moreover, SM are differently categorized and defined and evidences may be not comparable between studies. There is an urgent need of strategic guidelines and research investments aimed at prioritizing these populations disproportionately impacted by substance use. Equity-oriented policies and programs can facilitate opportunities and decrease substance use in these vulnerable subgroups, including community- and peer-led initiatives and nonjudgmental and inclusive health services.
- 19 May 2022
- Published by Taylor & Francis in International Review of Psychiatry
- Vol. 34 (3-4) , 423-431
The impact of discrimination on substance use disorders among sexual minorities
This paper aimed to review the literature regarding the impact of discrimination on substance use disorders among Sexual Minorities (SM), with a focus on alcohol, opioids, stimulants, polydrug use, chemsex, cannabis and tobacco, as well as inequalities in the access to health care services. It is alarmingly clear that SM report higher rates of morbidity if compared to the general population. Health care delivery inequalities have also been reported in this special population. Also, the lack of data from low- and middle-income countries on substance use among SM is a major concern. Certainly, discrimination play a key-role among leading factors to substance abuse, continued use, disorders, and lower levels of preventive and treatment interventions. However, it may be difficult to estimate the impact of discrimination because of the lack of research data and different methodologies of literature studies. Moreover, SM are differently categorized and defined and evidences may be not comparable between studies. There is an urgent need of strategic guidelines and research investments aimed at prioritizing these populations disproportionately impacted by substance use. Equity-oriented policies and programs can facilitate opportunities and decrease substance use in these vulnerable subgroups, including community- and peer-led initiatives and nonjudgmental and inclusive health services.